SELLAS Life Sciences Group, Inc. (SLS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, SELLAS Life Sciences reported revenue of $0. Net income was -$26.9M, or -$0.25 per diluted share. Operating activities generated -$28.4M of cash, leaving -$28.4M of free cash flow. At fiscal year end, SELLAS Life Sciences held $78.3M in total assets against $7.5M in total liabilities, including $71.8M of cash and equivalents.
Open the full interactive SELLAS Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
SELLAS Life Sciences Key Stats
| Share Price | $12.41 |
|---|---|
| Market Cap | $2.35B |
| 52-Week Range | $1.39 – $15.46 |
| Shares Outstanding | 189.2 million (basic, 2026 Q2) |
SELLAS Life Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $7.6M | $1.0M | $0 | $0 | $0 |
| Cost of Goods Sold | — | $200,000 | $100,000 | $0 | $0 | $0 |
| Gross Profit | — | $7.4M | $900,000 | $0 | $0 | $0 |
| Operating Income | -$17.0M | -$25.3M | -$42.0M | -$37.9M | -$31.5M | -$28.3M |
| Pre-Tax Income | -$16.8M | -$20.9M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| Income Tax | -$17,000 | -$237,000 | $0 | $0 | $0 | $0 |
| Net Income | -$16.8M | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| Diluted EPS | -$2.11 | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 |
SELLAS Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.8M | -$7.7M | -$8.4M | -$9.6M |
| Diluted EPS | -$0.06 | -$0.07 | -$0.05 | -$0.05 |
SELLAS Life Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.3M | $21.4M | $17.1M | $2.5M | $13.9M | $71.8M |
| Current Assets | $36.9M | $23.0M | $17.8M | $3.2M | $16.3M | $75.2M |
| Total Assets | $46.0M | $26.3M | $20.9M | $6.2M | $19.4M | $78.3M |
| Current Liabilities | $12.3M | $5.0M | $15.5M | $13.7M | $9.5M | $7.0M |
| Total Liabilities | $18.1M | $5.9M | $16.1M | $14.2M | $10.0M | $7.5M |
| Shareholders' Equity | $28.0M | $20.3M | $4.9M | -$8.0M | $9.5M | $70.9M |
SELLAS Life Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.4M | -$26.0M | -$23.8M | -$31.4M | -$35.4M | -$28.4M |
| Cash From Investing | — | — | -$4.5M | -$5.5M | $0 | — |
| Cash From Financing | $38.4M | $12.1M | $24.1M | $22.3M | $46.8M | $86.3M |
| Free Cash Flow | -$10.4M | -$26.0M | -$23.8M | -$31.4M | -$35.4M | -$28.4M |
Figures from SELLAS Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full SELLAS Life Sciences financials page for every line item.
SELLAS Life Sciences Company Profile
| Ticker | SLS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001390478 |
Frequently Asked Questions
What was SELLAS Life Sciences' revenue in fiscal 2025?
SELLAS Life Sciences (SLS) reported revenue of $0 for fiscal 2025.
What is SELLAS Life Sciences' annual revenue history?
SELLAS Life Sciences' annual revenue by fiscal year: 2020: $1.9M; 2021: $7.6M; 2022: $1.0M; 2023: $0; 2024: $0; 2025: $0.
What was SELLAS Life Sciences' net income in fiscal 2025?
SELLAS Life Sciences reported net income of -$26.9M for fiscal 2025.
What was SELLAS Life Sciences' earnings per share (EPS) in fiscal 2025?
SELLAS Life Sciences' diluted EPS was -$0.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did SELLAS Life Sciences generate in fiscal 2025?
SELLAS Life Sciences generated -$28.4M of free cash flow in fiscal 2025.
What was SELLAS Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), SELLAS Life Sciences reported revenue of $0.
How many shares of SELLAS Life Sciences are outstanding?
SELLAS Life Sciences reported a weighted average of 189.2 million basic shares outstanding in 2026 Q2.
What is SELLAS Life Sciences' market cap?
Based on its latest closing price, SELLAS Life Sciences (SLS) has a market capitalization of about $2.35B.
When does SELLAS Life Sciences' fiscal year end?
SELLAS Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is SELLAS Life Sciences headquartered?
SELLAS Life Sciences lists its business address in New York, New York in its SEC filings.